What Is a Cryobiopsy? Procedure, Uses, and Risks

A cryobiopsy is a tissue-sampling technique in which a thin probe is cooled to extremely low temperatures, freezing a small area of tissue so it sticks to the probe tip and can be pulled free in one piece. The procedure is performed most often through a bronchoscope threaded into the lungs, though the same principle applies to biopsies taken from airways, lymph nodes, and other sites. Compared with the conventional method of snipping tissue with tiny forceps, cryobiopsy consistently retrieves larger, better-preserved specimens, which gives pathologists more material to work with when trying to pin down a diagnosis.

How the Freezing Works

The cryoprobe is a slender, flexible catheter connected to a canister of compressed gas, usually nitrous oxide or carbon dioxide. When the gas is released through a narrow opening at the probe’s tip, it expands rapidly and the temperature plunges, sometimes to around −70 °C or lower. This rapid cooling is driven by what physicists call the Joule-Thomson effect: a gas that expands quickly without absorbing heat from an outside source drops in temperature on its own.¹ The tissue in contact with the tip freezes and bonds to the metal surface. After a few seconds of freezing, the doctor withdraws the probe and the frozen specimen comes with it. Once thawed, the tissue is placed in preservative and sent to the pathology lab.

Cryoprobes come in different diameters, commonly 1.1 mm and 2.4 mm. The smaller probe fits through thinner bronchoscope channels and reaches deeper into narrow airways, while the larger probe freezes a wider area and pulls a bigger sample. The choice depends on where the target is and how much tissue the pathologist needs. Freeze times are typically short, on the order of a few seconds, and freezing longer or using a bigger probe increases sample size but also raises the chance of complications like bleeding.

Why Bigger Specimens Matter

Traditional transbronchial biopsy uses small forceps that bite off tiny fragments of tissue. Those fragments are often crushed during the process, which can distort the architecture pathologists rely on to distinguish one disease from another. A meta-analysis comparing the two methods found that cryobiopsy specimens were substantially larger than forceps samples.² A randomized trial looking at mediastinal lymph nodes put numbers to the gap: a single cryobiopsy sample averaged about 8 mm² of tissue, while the combined tissue from three forceps passes averaged only about 2 mm².³ Beyond size, the frozen samples tend to preserve the tissue’s internal structure. Forceps can crush and squeeze, creating artifacts that make it harder for the pathologist to read. Cryobiopsy avoids much of that distortion because the freezing stiffens the tissue before it is pulled away.

For diseases where the pattern of damage across lung tissue is what clinches the diagnosis, having a large, intact sample can make the difference between a definitive answer and an inconclusive report. That advantage is especially relevant for interstitial lung diseases, where pathologists often need to see how inflammation and scarring are distributed across alveoli and small airways.

Interstitial Lung Disease, the Primary Use Case

Interstitial lung diseases are a broad family of conditions that cause scarring, inflammation, or other changes in the tissue between the air sacs of the lung. Getting the right diagnosis often requires a tissue sample, and for decades the gold standard was surgical lung biopsy, an operation performed under general anesthesia that involves cutting into the chest wall. Cryobiopsy has emerged as a less invasive alternative.

A large multicenter study of 373 patients with suspected interstitial lung disease found that cryobiopsy led to a definitive pathological diagnosis in roughly 63% of cases. Specimen sizes in that study ranged widely but had a median of about 17 mm².⁴ Earlier case series and small randomized trials reported diagnostic yields typically between 70% and 80%.⁵ Part of the variation comes down to protocol differences: the number of samples taken, the probe size, and whether the biopsy sites are chosen with the help of high-resolution CT imaging. Programs that target at least two biopsies from different airway segments, guided by CT findings, generally report higher yields with a favorable safety profile.⁶

How Cryobiopsy Compares to Surgical Lung Biopsy

The biggest selling point of cryobiopsy for interstitial lung disease is that it can deliver a comparable diagnosis without major surgery. A randomized trial, known as the COLD study, directly compared the two approaches. The diagnostic yield for multidisciplinary team diagnosis was about 89% for cryobiopsy and 88% for surgical biopsy, essentially identical. But the differences in invasiveness were striking: median hospital stay was zero days for cryobiopsy patients versus three and a half days for surgery, and serious adverse events other than chest-tube drainage occurred in one cryobiopsy patient compared with six in the surgical group.⁷ The trial’s conclusion was that a strategy starting with cryobiopsy and reserving surgery for inconclusive cases cuts adverse events and hospital time without sacrificing diagnostic accuracy.

That does not mean cryobiopsy has replaced surgical biopsy entirely. When cryobiopsy fails to give a clear answer, surgery remains the fallback. And in certain patterns of disease or when much larger samples are needed, a surgical approach still holds value. But for many patients, cryobiopsy offers a way to avoid the operating room altogether.

Beyond the Lung Tissue Itself

Although interstitial lung disease was where cryobiopsy first gained traction, the technique has spread to other clinical scenarios. Three deserve particular attention.

Endobronchial Lesions

When a tumor or suspicious growth is visible inside the airway, the cryoprobe can be pressed directly against it. Randomized trials have found that cryobiopsy produces larger tissue samples than forceps in endobronchial lesions, with one study reporting a diagnostic yield of roughly 75% for cryobiopsy versus 51% for forceps.⁸ Other trials have confirmed the size advantage.⁹ The larger, crush-free samples also help with molecular testing for targeted cancer therapies, which requires enough intact tissue to run genetic and protein analyses.

Peripheral Lung Nodules

Small nodules deep in the lung can be hard to reach with a bronchoscope, and harder still to biopsy adequately with forceps. Using a thin cryoprobe alongside image guidance, including fluoroscopy and radial endobronchial ultrasound, physicians can freeze and retrieve tissue from these peripheral targets.¹⁰ The 1.1-mm cryoprobe is especially useful here because it fits through the working channel of thinner bronchoscopes designed for navigating small airways.¹

Mediastinal Lymph Nodes

Enlarged lymph nodes in the mediastinum, the space between the lungs, often need to be sampled to diagnose or stage diseases like lung cancer, lymphoma, and sarcoidosis. The standard approach uses a needle guided by endobronchial ultrasound. That works well for many cancers, but it has a weakness: needle aspiration collects loose cells rather than intact tissue, so diseases that require preserved tissue architecture for accurate classification can be hard to diagnose. Lymphoma is the classic example.

Cryobiopsy performed through the airway wall under ultrasound guidance retrieves intact tissue cores from lymph nodes. A comprehensive review found that this technique had an overall diagnostic yield of about 92%, compared to roughly 77% for needle aspiration alone.¹¹ The advantage was especially pronounced for lymphoma: a systematic review reported cryobiopsy was diagnostic in about 87% of lymphoma cases versus only 12% for needle aspiration.¹² For benign conditions like sarcoidosis, cryobiopsy also showed a higher yield. A more recent within-patient accuracy study confirmed the pattern: cryobiopsy achieved 89% diagnostic accuracy versus about 82% for needle aspiration in the same patients, with the gap widest in lymphoproliferative diseases and benign conditions.¹³ Complications in these lymph-node studies were infrequent and minor.

Bleeding, the Main Risk

Because cryobiopsy pulls a larger chunk of tissue, it tears more blood vessels than forceps do. This makes bleeding the most common complication. A prospective, randomized, multicenter trial put the numbers side by side: any bleeding was seen in about 73% of cryobiopsy patients versus 48% after forceps biopsy. Most of that bleeding was mild and stopped on its own. Clinically significant bleeding, meaning moderate or severe, occurred in about 16% of cryobiopsy patients compared with roughly 4% of forceps patients. No fatal bleeding was reported.¹⁴

Other studies have reported moderate bleeding in a similar range. One series of 139 patients found moderate bleeding in 18% of cases, though all bleeding was controlled during the procedure using a two-scope technique in which a second bronchoscope is standing by to manage the biopsy site.¹⁵ A study specifically focused on patients with unclassifiable interstitial lung disease reported significant bleeding requiring extended balloon tamponade, intensive care, transfusion, or procedure abandonment in about 8% of cases.¹⁶

How Bleeding Is Managed

The most widely adopted safeguard against cryobiopsy bleeding is prophylactic balloon occlusion. Before taking the biopsy, a small balloon catheter is positioned in the airway leading to the biopsy site. As soon as the probe is withdrawn with the specimen, the balloon is inflated to block the airway and contain any bleeding. The blood pools behind the balloon while the body’s clotting mechanisms do their work, and the balloon is deflated a few minutes later once bleeding has stopped.

Whether the balloon absolutely needs to be placed before the biopsy or can be deployed reactively has been debated. A randomized controlled trial compared pre-placed balloons to a strategy where the balloon was available but not pre-placed, and found no significant difference in severe bleeding between the two groups, with severe bleeding at about 1–2% in both arms.¹⁷ Modified balloon techniques using smaller catheter sizes have also been described as reasonable options for bleeding prevention under flexible bronchoscopy.¹⁸ In practice, most expert centers keep a balloon ready regardless, even if they do not always pre-place it, because uncontrolled bleeding, though rare, can escalate quickly in the confined space of the airway.

Pneumothorax

Pneumothorax, where air leaks into the space between the lung and chest wall causing the lung to partially collapse, is the second most common complication. Because the biopsy is taken from within the lung, there is always some risk of puncturing through to the lung surface. Rates vary across studies. A large series of over a thousand patients reported pneumothorax in about 7% of cases, with nearly all requiring a chest drain; all drains were removed within four days and no prolonged air leaks occurred.¹⁹ A separate cohort of 699 patients showed a higher rate of about 19%, likely reflecting differences in patient selection and technique; in that study, the pneumothorax rate was tied to how compromised the patient’s baseline lung function was.²⁰

Fluoroscopy during the procedure helps reduce pneumothorax risk by allowing the physician to confirm that the cryoprobe tip is at a safe distance from the lung surface before activating the freeze. When a pneumothorax does occur, most are managed with a standard chest tube and resolve within a few days.

Who Can Safely Undergo the Procedure

Early on, many centers excluded patients considered high risk, including those with pulmonary hypertension, severe obstructive lung disease, or respiratory failure requiring supplemental oxygen. As experience has grown, some of those lines have been redrawn. A tertiary-center review specifically examined cryobiopsy in high-risk patients and concluded that the safety profile was acceptable even in those with respiratory failure, pulmonary hypertension, and moderate-to-severe obstructive disease. There was some incidence of moderate bleeding, but no deaths and no worsening of respiratory failure after the procedure.²¹

That said, contraindications still exist. Patients on anticoagulation therapy that cannot be safely paused, those with very low platelet counts, or those with severe uncontrolled pulmonary hypertension are generally not good candidates. Each center applies its own risk-benefit calculus, and the decision to proceed typically involves the pulmonologist, the anesthesia team, and the patient themselves.

Sedation and Anesthesia Approaches

Some centers perform cryobiopsy under general anesthesia with a rigid bronchoscope or a laryngeal mask airway, which gives the team maximum control over the airway if significant bleeding occurs. Others have demonstrated that the procedure can be done safely under conscious sedation with a flexible bronchoscope, particularly in settings where general anesthesia resources are limited. A study in a resource-constrained setting performed cryobiopsy under conscious sedation in 20 patients and reported two cases of pneumothorax (neither requiring intervention) and one case of bleeding controlled with a balloon blocker. There were no complications related to the sedation itself.²²

The trade-off is control versus accessibility. General anesthesia allows the physician to manage the airway without worrying about patient coughing or movement during biopsy, and it provides a secure route for instruments if bleeding needs to be addressed urgently. Conscious sedation is lighter, less resource-intensive, and lets the patient go home sooner, but demands a team that is prepared for rapid escalation if something goes wrong. Both approaches are in use around the world, and neither has been established as clearly superior in head-to-head trials for cryobiopsy specifically.

Where Cryobiopsy Fits in a Diagnostic Workup

Cryobiopsy is not the first test a doctor orders when a lung problem is suspected. Imaging comes first, usually a chest CT scan. Blood tests, pulmonary function testing, and sometimes bronchoalveolar lavage (flushing fluid into the lung and collecting it for analysis) help narrow the possibilities. A multidisciplinary team, typically including a pulmonologist, a radiologist, and a pathologist, reviews all of this information and decides whether a tissue biopsy will change the management plan. If it will, the next question is which biopsy route to use.

For many patients with suspected interstitial lung disease, cryobiopsy has become the preferred tissue-sampling method because it delivers diagnostic-quality specimens without the morbidity of surgery. For suspected lung cancer in peripheral nodules, it competes with CT-guided needle biopsy through the chest wall, which has its own risk of pneumothorax and bleeding but does not require bronchoscopy. For mediastinal lymph nodes, cryobiopsy is increasingly used as an add-on to standard needle aspiration when the initial needle sample comes back non-diagnostic or when lymphoma is suspected from the outset. There is no universal algorithm; the choice reflects a combination of clinical suspicion, lesion location, patient fitness, and local expertise.

What Happens to the Sample After It Is Taken

Once the frozen tissue is freed from the probe tip, it thaws quickly at room temperature or in saline. The specimen is then placed in formalin or another preservative and sent to the pathology department, where it is processed into thin slices, stained, and examined under a microscope. The hallmark advantage of cryobiopsy tissue is well-preserved architecture: the relationship between cells, blood vessels, and connective tissue remains largely intact, which is why pathologists can often make a definitive diagnosis from cryobiopsy specimens that would have been inconclusive from crushed forceps samples.

For cancer diagnosis specifically, having intact tissue opens the door to immunohistochemistry (staining for specific proteins on cell surfaces) and molecular testing (looking for genetic mutations that guide targeted therapy). These techniques need a minimum amount of tissue, and cryobiopsy’s larger specimens help meet that threshold. This matters most in lung cancer, where treatment decisions increasingly hinge on the molecular profile of the tumor rather than just its appearance under the microscope.